Abstract
Twelve patients with rectal carcinoma were treated for 2 weeks with the somatostatin analogue SMS 201.995. Effects of this therapy were assessed using serum marker concentration, Ki67 and gastrin-immunoreactivity of the primary tumour. In four out of 12 patients, a significant decrease in Ki67 immunoreactivity was seen during SMS 201.995 treatment while in the remaining eight patients there was no significant change in Ki67 expression. Four patients had elevated pretreatment serum carcinoembryonic antigen (CEA) levels. In two of these four patients, serum CEA levels fell modestly during SMS 201.995 therapy. This is the first clinical evidence that a somatostatin analogue can inhibit the growth of some colorectal cancers.
Highlights
The aim of the present study is to evaluate the effect of subcutaneously administered SMS 201.995 on both the change in serum tumour marker concentrations and in tumour kinetics, as assessed by Ki67 immunoreactivity, in patients with primary rectal carcinoma
None had liver metastases either clinically or on intra-operative contact ultrasonography. In two of these four patients, there was a modest reduction in serum carcinoembryonic antigen (CEA) levels during SMS 201.995 therapy
Post-resection serum CEA levels fell below pre-operative levels, as would be expected
Summary
The aim of the present study is to evaluate the effect of subcutaneously administered SMS 201.995 on both the change in serum tumour marker concentrations and in tumour kinetics, as assessed by Ki67 immunoreactivity, in patients with primary rectal carcinoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
